- Home
- WBS vs ROIV Comparison
WBS vs ROIV Comparison
Compare WBS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WBS | ROIV |
|---|---|---|
| Founded | 1935 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WBS | ROIV |
|---|---|---|
| Price | $64.10 | $22.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $72.08 | $24.31 |
| AVG Volume (30 Days) | 1.4M | ★ 8.2M |
| Earning Date | 01-16-2026 | 02-09-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | ★ 21.39 | N/A |
| EPS | ★ 5.36 | N/A |
| Revenue | ★ $2,581,185,000.00 | $20,329,000.00 |
| Revenue This Year | $8.54 | N/A |
| Revenue Next Year | $4.32 | $376.94 |
| P/E Ratio | $12.06 | ★ N/A |
| Revenue Growth | ★ 8.65 | N/A |
| 52 Week Low | $39.43 | $8.73 |
| 52 Week High | $65.39 | $23.47 |
Technical Indicators
Market Signals| Indicator | WBS | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 70.61 | 61.61 |
| Support Level | $63.26 | $21.60 |
| Resistance Level | $65.39 | $23.47 |
| Average True Range (ATR) | 1.28 | 0.88 |
| MACD | 0.14 | 0.06 |
| Stochastic Oscillator | 79.90 | 69.09 |
Price Performance
Historical ComparisonAbout WBS Webster Financial Corporation
Webster Financial Corp is a full-service provider of financial services, offering commercial and consumer banking, mortgages, and investment advisory along with trust and wealth management services in Connecticut, New York, Rhode Island, Massachusetts, and Pennsylvania. The company's segment includes Commercial Banking, HSA Bank, and Consumer Banking. It generates maximum revenue from the Commercial Banking segment.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.